{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:21:31Z","timestamp":1768706491652,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The adverse effects of neuromuscular junction dysfunctions caused by immune checkpoint inhibitor (ICI) drugs have not been thoroughly assessed in the clinics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the neuromuscular junction dysfunctions in cancer patients with adverse events caused by ICI therapy by searching the Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The FAERS data from January 2004 to December 2020 were collected to analyze the association between neuromuscular connection dysfunction and ICI use. Disproportionate analysis and Bayesian analysis were used to quantify the association between the neuromuscular junction dysfunctions and ICIs. The onset time and outcome of neuromuscular junction dysfunctions in different ICI regimens were also compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 88,617 adverse event reports, 557 neuromuscular junction dysfunction reports (0.63%) were analyzed. Marketed ICI drugs, including ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab, avelumab, as well as their combinations, showed positive associations with four detection methods. Most of the adverse event reports were associated with the use of nivolumab (53.32%) and pembrolizumab (31.96%). However, nivolumab-related neuromuscular junction dysfunctions were similar with pembrolizumab (33.33% vs 33.14%, p &amp;gt; 0.05). The onset time of neuromuscular junction dysfunctions showed no significant difference among different ICIs (p &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Analysis of FAERS data identified that over 30% (32.85%) of reports of neuromuscular junction dysfunctions resulted in death. Ongoing monitoring, risk evaluations, and further comparative studies of ICIs should be\u00a0considered.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.778635","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T08:52:47Z","timestamp":1661244767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years"],"prefix":"10.3389","volume":"13","author":[{"given":"Ping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109437","article-title":"Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy","volume":"120","author":"Liu","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-Related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12339","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment","author":"Psimaras","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26070","article-title":"Neuromuscular complications of immune checkpoint inhibitor therapy","volume":"58","author":"Kolb","year":"2018","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan","year":"2021","journal-title":"ESMO Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.89","article-title":"The FDA drug safety surveillance program: adverse event reporting trends","volume":"171","author":"Weiss-Smith","year":"2011","journal-title":"Arch Intern Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B18","article-title":"Explaining odds ratios","volume":"19","author":"Szumilas","year":"2010","journal-title":"J Can Acad Child Adolesc Psych"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2014","article-title":"Selected control events and reporting odds ratio in signal detection methodology","volume":"19","author":"Ooba","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Noren","year":"2006","journal-title":"Stat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C515","article-title":"A brief primer on automated signal detection","volume":"37","author":"Hauben","year":"2003","journal-title":"Ann Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian Data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Statistician"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: An overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin Ther"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.5772\/50095","article-title":"Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS)","volume-title":"Data mining applications in engineering and medicine","author":"Poluzzi","year":"2012"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cbpa.2018.05.006","article-title":"Recent progress in therapeutic antibodies for cancer immunotherapy","volume":"44","author":"Lee","year":"2018","journal-title":"Curr Opin Chem Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.778635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T08:52:52Z","timestamp":1661244772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.778635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2022.778635"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.778635","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"778635"}}